Sagimet Biosciences
SGMT
88 hedge funds and large institutions have $69.8M invested in Sagimet Biosciences in 2026 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 18 reducing their positions, and 13 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 18
52% more call options, than puts
Call options by funds: $1.72M | Put options by funds: $1.14M
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
2% more funds holding
Funds holding: 86 → 88 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.73% less ownership
Funds ownership: 46.43% → 41.71% (-4.7%)
18% less capital invested
Capital invested by funds: $85.2M → $69.8M (-$15.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.58M |
| 2 |
Millennium Management
New York
|
+$1.53M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.04M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$753K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$514K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
-$5.07M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$4.29M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
-$1.56M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$916K |
| 5 |
Jane Street
New York
|
-$419K |
SGMT Hedge Fund Activity: Q1 2026 in Review
88 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q1 2026, worth a combined $69.8M — down 18% from $85.2M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SGMT positions and 13 closed out — a net gain of 5 holders — while 32 added to existing stakes and 18 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.58M. The largest seller was Blue Owl Capital Holdings, cutting an estimated $5.07M.
- 88 institutional investors held Sagimet Biosciences (SGMT) as of Q1 2026, up from 86 in Q4 2025.
- Funds reported $69.8M of Sagimet Biosciences stock for Q1 2026, down 18% quarter-over-quarter.
- 18 funds opened new Sagimet Biosciences positions in Q1 2026 and 13 closed out, a net change of +5 holders.
- The largest Sagimet Biosciences buyer in Q1 2026 was Renaissance Technologies, an estimated $1.58M added.
- The largest Sagimet Biosciences seller in Q1 2026 was Blue Owl Capital Holdings, an estimated $5.07M sold.
Based on aggregated 13F filings for Q1 2026.